Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies
Abstract
Conjugate vaccines have proven to be an effective and safe strategy for reducing the incidence of disease caused by bacterial pathogens. However, the manufacture of these vaccines is technically demanding, inefficient, and expensive, thereby limiting their widespread use. Here, we describe an alternative methodology for generating glycoconjugate vaccines whereby recombinant polysaccharide biosynthesis is coordinated with vesicle formation in nonpathogenic Escherichia coli , resulting in glycosylated outer membrane vesicles (glycOMVs) that can effectively deliver pathogen-mimetic glycotopes to the immune system. An attractive feature of our approach is the fact that different plasmid-encoded polysaccharide biosynthetic pathways can be readily transformed into E. coli , enabling a “plug-and-play” platform for the on-demand creation of glycOMV vaccine candidates that carry heterologous glycotopes from numerous pathogenic bacteria.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 06, 2016
- Source ID
- 10.1073/pnas.1518311113
Entities
People
- Bradley D. Jones
- Christian Heiss
- Christine E. Endicott
- Chung-jr Huang
- David Putnam
- Jed A. Rasmussen
- Jenny L. Valentine
- Joseph A. Rosenthal
- Joseph M. Boll
- Joshua R. Fletcher
- Justyna Dobruchowska
- Linxiao Chen
- M Stephen Trent
- Matthew P. DeLisa
- Parastoo Azadi
- Tyler D Moeller
- Zhirui Wang
Organizations
- Army Research Office
- Cornell University
- National Institutes of Health
- National Science Foundation
- United States Department of Energy
- University of Georgia
- University of Iowa
- University of Texas at Austin